首页> 外文OA文献 >Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

【2h】

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

机译：Folfoxiri加贝伐单抗的原发性肿瘤和益处作为转移性结直肠癌的初始治疗。 Gono的Tribe审判回顾性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
C. Cremolini; C. Antoniotti; S. Lonardi; F. Bergamo; E. Cortesi; G. Tomasello; R. Moretto; M. Ronzoni; P. Racca; F. Loupakis; A. Zaniboni; G. Tonini; A. Buonadonna; F. Marmorino; G. Allegrini; C. Granetto; G. Masi; V. Zagonel; E. Sensi; G. Fontanini; L. Boni; A. Falcone;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO [J] . Cremolini C., Antoniotti C., Lonardi S., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第7期

机译：Folfoxiri加贝伐单抗作为转移性结直肠癌的初始治疗，原发性肿瘤等性和益处。戈诺的部落审判回顾性分析
2. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO [J] . Daniele Rossini, Sara Lonardi, Carlotta Antoniotti, British Journal of Cancer . 2021,第1期

机译：在转移性结直肠癌中的第一线叶氟脲和贝伐单抗的进展后的治疗方法：Gono的部落和Tribe2研究汇总分析
3. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial [J] . The lancet oncology . 2020,第4期

机译：Upfront folfoxiri加贝伐单抗和进展后的重新引入与mfolfox6加上贝伐单抗，其次是Folfiri加贝伐单抗在治疗转移性结肠直肠癌（TRIBE2）：多期，开放标签，第3阶段，随机，受控试验
4. High-Depth Sequencing of Over 750 Genes Supports Linear Progression of Primary Tumors and Metastases in the Majority of Patients with Liver-Limited Metastatic Colorectal Cancer [C] . Simeen Malik, Iain Beehuat Tan, Kalpana Ramnarayanan, International Molecular Medicine Tri-Conference. . 2015

机译：超过750个基因的高深度测序支持肝脏有限转移性结直肠癌大多数患者的原发性肿瘤和转移的线性进展
5. Improving the Delivery of Novel Molecularly-targeted Therapies for the Treatment of Primary and Metastatic Brain Tumors [D] . Gampa, Gautham 2019

机译：改善新型分子靶向疗法在治疗原发性和转移性脑肿瘤中的作用
6. Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients [O] . Xia-Hong You, Can Wen, Zi-Jin Xia, 2007

机译：原发性肿瘤的副作用预测贝伐单抗在转移性结直肠癌患者中的益处
7. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial [O] . Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, 2020

机译：Upfront folfoxiri加贝伐单抗和次曲后的重新引入与mfolfox6 plus bevacizumab，然后是Folfiri加Bevacizumab治疗转移性结肠直肠癌（Tribe2）：多期，开放标签，第3阶段，随机，受控试验

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

著录项

引文网络

相似文献

相关主题

期刊订阅